Advocacy intelligence hub — real-time data for patient organizations
SYLVANT: FDA approved
Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
SYLVANT
Recordati Rare Diseases Inc.
SYLVANT
(siltuximab)Orphan drugRecordati Rare Diseases Inc.
Interleukin-6 Antagonist [EPC]
12.1 Mechanism of Action Siltuximab binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors. IL-6 has been...
Robert Yarchoan, M.D.
National Cancer Institute (NCI)
📍 Bethesda, Maryland
Ramya M Ramaswami, M.D.
National Cancer Institute (NCI)
📍 Bethesda, Maryland
Joshua Brandstadter, MD, PhD, MSc, M.D., PhD
University of Pennsylvania
📍 PHILADELPHIA, PA
Pier Luigi Zinzani, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Matthew Painschab, MD, MD
University of North Carolina
📍 INDIANAPOLIS, IN
Vera Krymskaya, PhD, MBA
University of Pennsylvania